Global Biologics Manufacturer with More than 90 Years Experience Leverages Capabilities to Accelerate Human Vaccine Development
IDT Biologika announced the dedication of its first U.S. vaccine manufacturing facility in Rockville, Maryland. The state-of-the-art facility provides the translational bridge between pre-clinical development and phase II clinical trials with end-to-end capabilities, including process development, cell banking, cGMP manufacturing, purification and formulation, and fill and finish.
“The Rockville facility marks a milestone for IDT Biologika as we expand our worldwide operations into the United States and continue our commitment to meet the vaccine development and production needs in key markets,” said IDT Biologika Corporation President Dr. Ralf Pfirmann. “With the new facility, we provide U.S. companies with a highly capable and experienced CMO-partner for phase I and phase II clinical vaccine projects right from the heart of the BioMaryland corridor.”
The Rockville facility is BSL-2 compliant and meets all U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards. IDT Biologika shares the 75,000-foot building with Aeras, a nonprofit, global biotech organization developing new tuberculosis vaccines for the world, and is partnering with the nonprofit organization on process development and manufacturing of candidate tuberculosis vaccines.
“We’re very pleased that IDT Biologika, a world-class vaccine manufacturer, has chosen Maryland as the location for its first U.S. manufacturing facility,” said Ben Wu, Deputy Secretary of the Maryland Department of Business and Economic Development. “IDT Biologika’s decision to locate here is another example of how international companies are viewing Maryland as a prime location for their cutting-edge research and discoveries that are improving the lives of people across the globe. Our state is home to to many vaccine, biotechnology and pharmaceutical companies, to renowned academic institutions, and to government agencies vital to the development of vaccines.”
Aeras is a nonprofit biotech advancing the development of tuberculosis vaccines for the world. In collaboration with global partners in Africa, Asia, North America and Europe, Aeras is supporting the clinical testing of six experimental vaccines as well as a robust portfolio of earlier stage candidates. Aeras receives funding from the Bill & Melinda Gates Foundation, the UK Department for International Development, the Netherlands’ Ministry of Foreign Affairs, Australian AID, and a range of other governments. Aeras is based in Rockville, Maryland; Cape Town, South Africa; and Beijing, China. www.aeras.org
Founded in 1921 the company focuses on three core areas – animal health, vaccines and pharmaceuticals. IDT Biologika offers innovative solutions for next generation vaccines. IDT Biologika, a global leader in MVA technology, develops new technologies for multiple innovative vaccines. The company offers development services and manufacturing facilities for clinical phase I to III as well as commercial supplies for leading-edge viral and bacterial human and animal health vaccines. IDT Biologika is one of the few companies worldwide with the capacity for large-scale campaign manufacture of vaccine batches of different vaccine products using multipurpose production technology. IDT Biologika is a company of the Klocke Holding Group. The Klocke Holding Group companies specialize in contract manufacturing and packaging of pharmaceuticals, vaccines, and cosmetic products. With more than 1,800 employees at six locations in Europe and the USA, the traditionally family-owned Klocke Group offers comprehensive services for production and packaging of pharmaceutical products.